Evaluation of pentoxifylline in the treatment of necrobiosis lipoidica: outcomes in 10 patients

International Journal of DermatologyEarly View Clinical Correspondence Evaluation of pentoxifylline in the treatment of necrobiosis lipoidica: outcomes in 10 patients Matthew L. Hrin, Corresponding Author Matthew L. Hrin [email protected] orcid.org/0000-0002-2769-3156 Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USASearch for more papers by this authorMax Oscherwitz, Max Oscherwitz orcid.org/0000-0003-4572-5032 Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USASearch for more papers by this authorJoseph L. Jorizzo, Joseph L. Jorizzo Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USASearch for more papers by this authorSteven R. Feldman, Steven R. Feldman Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA Department of Dermatology, University of Southern Denmark, Odense, DenmarkSearch for more papers by this authorWilliam W. Huang, William W. Huang Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USASearch for more papers by this author Matthew L. Hrin, Corresponding Author Matthew L. Hrin [email protected] orcid.org/0000-0002-2769-3156 Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USASearch for more papers by this authorMax Oscherwitz, Max Oscherwitz orcid.org/0000-0003-4572-5032 Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USASearch for more papers by this authorJoseph L. Jorizzo, Joseph L. Jorizzo Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USASearch for more papers by this authorSteven R. Feldman, Steven R. Feldman Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA Department of Dermatology, University of Southern Denmark, Odense, DenmarkSearch for more papers by this authorWilliam W. Huang, William W. Huang Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USASearch for more papers by this author First published: 18 January 2024 https://doi.org/10.1111/ijd.17037 Reviewed and approved by Wake Forest University Health Sciences IRB00075066. Conflict of interest: Steven Feldman has received research, speaking, and/or consulting support from a variety of companies including Galderma, GSK/Stiefel, Almirall, Leo Pharma, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, Abbvie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate, and National Psoriasis Foundation. He is founder and majority owner of www.DrScore.com and founder and part owner of Causa Research, a company dedicated to enhancing patients' adherence to treatment. The remaining authors have no conflicts to disclose. Funding source: None. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Reid SD, Ladizinski B, Lee K, Baibergenova A, Alavi A. Update on necrobiosis lipoidica: a review of etiology, diagnosis, and treatment options. J Am Acad Dermatol. 2013; 69: 783–791. 10.1016/j.jaad.2013.05.034 PubMedWeb of Science®Google Scholar 2Wee E, Kelly R. Pentoxifylline: an effective therapy for necrobiosis lipoidica. Australas J Dermatol. 2017; 58: 65–68. 10.1111/ajd.12420 PubMedWeb of Science®Google Scholar 3Basaria S, Braga-Basaria M. Necrobiosis lipoidica diabeticorum: response to pentoxiphylline. J Endocrinol Invest. 2003; 26: 1037–1040. 10.1007/BF03348204 CASPubMedWeb of Science®Google Scholar 4Noz KC, Korstanje MJ, Vermeer BJ. Ulcerating necrobiosis lipoidica effectively treated with pentoxifylline. Clin Exp Dermatol. 1993; 18: 78–79. 10.1111/j.1365-2230.1993.tb00977.x CASPubMedWeb of Science®Google Scholar 5Hashemi DA, Brown-Joel ZO, Tkachenko E, Nelson CA, Noe MH, Imadojemu S, et al. Clinical features and comorbidities of patients with necrobiosis lipoidica with or without diabetes. JAMA Dermatol. 2019; 155: 455–459. 10.1001/jamadermatol.2018.5635 PubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation